Keywords: btg, acquire, protherics, l218m, uk, drug, developer

BTG to acquire Protherics for L218M

Article | 22 September 2008

UK drug developer BTG has agreed to acquire biopharmaceutical firm Protherics for L218.1 million ($391.2 million), or 60 pence per share, a 45.5% ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Astra Zeneca

AstraZeneca

Go to company listing